A3P Biomedical

Executive Summary

A3P Biomedical is a Swedish diagnostics company dedicated to improving early detection of prostate cancer through its flagship product, Stockholm3. This clinically validated blood test combines protein biomarkers, genetic markers, and clinical data to assess the risk of aggressive prostate cancer, aiming to reduce unnecessary biopsies while improving detection of clinically significant cancers. Founded in 2006 and headquartered in Uppsala, the company operates in the diagnostics sector with a focus on addressing a critical unmet need in prostate cancer screening. Stockholm3 has been validated in multiple studies and is already used in several European countries, positioning A3P as a key player in the shift toward more precise, risk-based screening paradigms. The global prostate cancer diagnostics market is substantial, with growing demand for non-invasive, accurate tests that reduce overdiagnosis and healthcare costs. Stockholm3's ability to identify high-risk patients while minimizing false positives offers a compelling value proposition for healthcare systems and payers. A3P's strategy includes expanding geographic reach, pursuing regulatory approvals in new markets, and securing reimbursement. With increasing awareness of the limitations of PSA-based screening, Stockholm3 is well positioned to capture market share. The company's future growth hinges on successful commercialization, further clinical evidence, and strategic partnerships, making it an attractive opportunity in the precision diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026US FDA 510(k) clearance for Stockholm360% success
• H1 2027Inclusion in European Association of Urology (EAU) guidelines50% success
• Q2 2027Commercial partnership with a major US laboratory for national rollout40% success